投資概要
中國中藥2017年上半年強勁的業務表現證實了我們之前的預測。隨著配藥機裝配到更多醫院，中國中藥進一步鞏固領先的市場地位並為未來醫院終端的競爭做準備。公司的全產業鏈佈局隨著對上下游的兼併與收購持續推進。我們看好中藥配方顆粒業務的良好前景，維持“買入”評級，目標價5.70港元。(現價截至10月19日)
Graduated from Hong Kong Polytechnic University, Master of Finance (Investment Management). Possess bachelor degree majoring in Financial Management from Southwestern University of Finance and Economics. Focus on industry prospect and corporate fundamentals to explore investment value and cover pharmaceutical and consumer industry.
